BioSpace News Archive

Heidelberg Ion Beam Therapy Center (HIT) has treated its first patient using helium ion therapy with RayStation®* treatment planning system.

Sonendo, Inc., a leading dental technology company and developer of the GentleWave® System, announced that it has launched the roadshow for its initial public offering of shares of its common stock.

Humanigen, Inc. (Nasdaq: HGEN), today announced the European Commission identified lenzilumab as one of the “10 most promising treatments for COVID-19” in a report and press release issued on October 22, 2021.

Air Products (NYSE: APD), a global leader in industrial gases and cryogenic technology, and Sublime Stericeuticals Corporation, a process design and equipment manufacturer serving the pharmaceutical industry, today announced plans to collaborate and develop a proprietary sublimation and desorption technology for a continuous freeze-drying system for vaccine and drug solutions.

About half of patients with appendicitis do not need an appendectomy procedure up to four years after receiving a course of antibiotics, according to final results of the Comparison of Outcomes of antibiotic Drugs and Appendectomy (CODA) trial.

Varian, a Siemens Healthineers company, and the Cincinnati Children’s/UC Health Proton Therapy Center today announced the completion of enrollment in FAST-01 (FeAsibility Study of FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases), the first human clinical trial of FLASH therapy.

SMART Medical Systems Ltd., a developer and manufacturer of innovative endoscopy products, today reported positive data from a multicenter clinical study (NCT 04708951) comparing the adenoma detection rate (ADR) of its FDA-cleared G-EYE® balloon technology against ENDOCUFF VISION® (ECV) technology in patients undergoing screening or surveillance colonoscopy.

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its third quarter financial results on Thursday, November 4, 2021.

Revelation Biosciences Inc. (Revelation), announced today that it engaged Destum Partners Inc. to assist in finding an Ex-US development partner for its therapeutic product candidate REVTx-99, and development partner(s) worldwide for its therapeutic product candidate REVTx-200.

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), announced today that is has closed its previously announced underwritten public offering of 8,712,400 shares of its common stock,